Literaturverzeichnis
zum Titelthema „Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms“, Bayerisches Ärzteblatt 6/2015, Seite 280 ff.
von Professor Dr. Matthias W. Beckmann, Professor Dr. Rüdiger Schulz-Wendtland und Dr. Claudia Rauh
1. Krebs in Deutschland 2009/2010. 9. Ausgabe ed. 2013, Berlin.
2. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms 2012, Leitlinienprogramm Onkologie der AWMF, Deutschen Krebsgesellschaft e.V. und Deutschen Krebshilfe e.V. : Berlin.
3. Albert, U.S., et al., 2008 update of the guideline: early detection of breast cancer in Germany. J Cancer Res Clin Oncol, 2009. 135(3): p. 339-54.
4. Bleyer, A. and H.G. Welch, Effect of three decades of screening mammography on breast-cancer incidence. N Engl J Med, 2012. 367(21): p. 1998-2005.
5. Tilanus-Linthorst, M.M., et al., Hereditary breast cancer growth rates and its impact on screening policy. Eur J Cancer, 2005. 41(11): p. 1610-7.
6. Veronesi, U., et al., Twenty-year follow-up of a randomized study comparing breast- conserving surgery with radical mastectomy for early breast cancer. New England Journal of Medicine, 2002. 347(16): p. 1227-1232.
7. Krag, D.N., et al., Sentinel-lymph-node resection compared with conventional axillary- lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol, 2010.
11(10): p. 927-33.
8. Giuliano, A.E., et al., Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA, 2011.
305(6): p. 569-75.
9. Early Breast Cancer Trialists' Collaborative, G., et al., Effect of radiotherapy after breast- conserving surgery on 10-year recurrence and 15-year breast cancer death: meta- analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 2011. 378(9804): p. 1707-16.
10. Bartelink, H., et al., Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol, 2007. 25(22): p. 3259-65.
11. Haviland, J.S., et al., The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol, 2013. 14(11): p. 1086-94.
12. Moebus, V., et al., Intense dose-dense sequential chemotherapy with epirubicin,
paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol, 2010. 28(17): p. 2874-80.
13. Perez, E.A., et al., Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol, 2011. 29(25): p. 3366-73.
14. Petrelli, F. and S. Barni, Should adjuvant trastuzumab be offered in very early-stage (pT1a/bN0M0) HER2-neu-positive breast cancer? A current debate. Medical Oncology, 2011. 28(2): p. 401-408.
15. Davies, C., et al., Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet, 2013. 381(9869): p. 805-16.
16. Francis, P.A., et al., Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med, 2015. 372(5): p. 436-46.
17. Aebi, S., et al., Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. Lancet Oncol, 2014. 15(2): p. 156-63.
18. Nach: Wittekind, C, Meyer, H.J., Bootz, F.: TNM-Klassifikation maligner Tumoren, 6. Auflage. Springer-Verlag, Berlin Heidelberg New York, 2002
